Paul Ciclitira

Paul Ciclitira


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JLJonathan Landy
Jonathan Landy
EREmma Ronde
Emma Ronde
NENick English
Nick English
SCSue K Clark
Sue K Clark
AHAilsa L Hart
Ailsa L Hart
HAHafid Omar Al-Hassi
Hafid Omar Al-Hassi
Inflammatory bowel diseases are characterised by inflammation that compromises the integrity of the epithelial barrier. The intestinal epithelium is not only a static barrier but has evolved complex mechanisms to control and regulate bacterial interactions with the mucosal surface. Apical tight junction proteins are critical in the maintenance of epithelial barrier function and control of paracellular permeability. The characterisation of alterations in tight junction proteins as key players in epithelial barrier function in inflammatory bowel diseases is rapidly enhancing our understanding of critical mechanisms in disease pathogenesis as well as novel therapeutic opportunities. Here we give an overview of recent literature focusing on the role of tight junction proteins, in particular claudins, in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer.

1 January 2012 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DDDavid H Dewar
David H Dewar
SDSuzanne C Donnelly
Suzanne C Donnelly
SMSimon D McLaughlin
Simon D McLaughlin
MJMatthew W Johnson
Matthew W Johnson
HEH Julia Ellis
H Julia Ellis
PCPaul Ciclitira
Paul Ciclitira
To investigate all patients referred to our center with non-responsive celiac disease (NRCD), to establish a cause for their continued symptoms. We assessed all patients referred to our center with non-responsive celiac disease over an 18-mo period. These individuals were investigated to establish the eitiology of their continued symptoms. The patients were first seen in clinic where a thorough history and examination were performed with routine blood work including tissue transglutaminase antibody measurement. They were also referred to a specialist gastroenterology dietician to try to identift any lapses in the diet and sources of hidden gluten ingestion. A repeat small intestinal biopsy was also performed and compared to biopsies from the referring hospital where possible. Colonoscopy, lactulose hydrogen breath testing, pancreolauryl testing and computed tomography scan of the abdomen were undertaken if the symptoms persisted. Their clinical progress was followed over a minimum of 2 years. One hundred and twelve consecutive patients were referred with NRCD. Twelve were found not to have celiac disease (CD). Of the remaining 100 patients, 45% were not adequately adhering to a strict gluten-free diet, with 24 (53%) found to be inadvertently ingesting gluten, and 21 (47%) admitting non-compliance. Microscopic colitis was diagnosed in 12% and small bowel bacterial overgrowth in 9%. Refractory CD was diagnosed in 9%. Three of these were diagnosed with intestinal lymphoma. After 2 years, 78 patients remained well, eight had continuing symptoms, and four had died. In individuals with NRCD, a remediable cause can be found in 90%: with continued gluten ingestion as the leading cause. We propose an algorithm for investigation.

21 November 2003 in Gut
Verified
Journal Article
Open access
PDF file
JFJ S Fraser
J S Fraser
WEW Engel
W Engel
HEH J Ellis
H J Ellis
SMS J Moodie
S J Moodie
EPE L Pollock
E L Pollock
PCPaul Ciclitira
Paul Ciclitira
Background: Peptides from α-gliadins have been used to characterise the immunodominant coeliac toxic epitope. A peptide corresponding to amino acid residues 57–73 of A-gliadin causes peripheral blood mononuclear cells from coeliac patients to secrete interferon γ (IFN-γ); gluten specific small intestinal T cell clones proliferate in response to peptides corresponding to residues 57–68 and 62–75 of α-gliadins. We wished to investigate whether a peptide corresponding to residues 56–75 of α-gliadins exacerbates coeliac disease in vivo. Methods: Four adults with coeliac disease, all of whom were on a gluten free diet, underwent three challenges. Peptic-tryptic gliadin (PTG 1 g) served as a positive control. The test peptide and a negative control peptide were studied on separate occasions. The peptides were instilled into the duodenum and biopsies were taken before the infusion, and two, four, and six hours after commencing the infusions, using a Quinton hydraulic multiple biopsy capsule. Biopsy specimens were assessed blindly for villus height to crypt depth ratio (VH:CD), enterocyte cell height (ECH), and intraepithelial lymphocyte (IEL) count. We used the Mann-Whitney U test, with 95% confidence intervals, for statistical analysis. Results: VH:CD and ECH fell, and IEL increased significantly 4–6 hours after commencing infusions with both PTG and the test peptide in all subjects. The negative control peptide caused no significant changes to villus morphology, enterocyte height, or IEL count in any patient. Conclusion: We have confirmed that the putative immunodominant epitope, a peptide corresponding to residues 56–75 of α-gliadins, exacerbates coeliac disease in vivo.

1 November 2000 in Annals of Human Genetics
Verified
Journal Article
Open access
PDF file
AKA. L. King
A. L. King
JYJ. Y. Yiannakou
J. Y. Yiannakou
PBP. M. Brett
P. M. Brett
DCD. Curtis
D. Curtis
MMM.‐A. Morris
M.‐A. Morris
PCPaul Ciclitira
Paul Ciclitira
The susceptibility to develop coeliac disease (CD) has a strong genetic component, which is not entirely explained by HLA associations. Two previous genome wide linkage studies have been performed to identify additional loci outside this region. These studies both used a sib‐pair design and produced conflicting results.Our aim is to identify non‐MHC genetic loci contributing to coeliac disease using a family based linkage study. We performed a genome wide search in 16 highly informative multiply affected pedigrees using 400 microsatellite markers with an average spacing of 10 cM. Linkage analysis was performed using lod score and model free methods.We identified two new potential susceptibility loci with lod scores of 1.9, at 10q23.1, and 16q23.3. Significant, but lower lod scores were found for 6q14 (1.2), 11p11 (1.5), and 19q13.4 (0.9), areas implicated in a previous genome wide study. Lod scores of 0.9 were obtained for both D7S507, which lies 1 cM from the γT‐cell receptor gene, and for D2S364, which lies 12 cM from the CTLA4 gene.

25 August 2005 in Molecular Aspects of Medicine
Verified
Journal Article
Closed access
PCPaul Ciclitira
Paul Ciclitira
MJMathew W. Johnson
Mathew W. Johnson
DDDavid H. Dewar
David H. Dewar
HEH. Julia Ellis
H. Julia Ellis

1 June 2005 in Best Practice & Research Clinical Gastroenterology
Verified
Journal Article
Closed access
PCPaul Ciclitira
Paul Ciclitira
HEH. Julia Ellis
H. Julia Ellis
KLKnut E.A. Lundin
Knut E.A. Lundin